

INVIVO THERAPEUTICS HOLDINGS CORP.  
Form 8-K  
December 20, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**  
**CURRENT REPORT PURSUANT TO**  
**SECTION 13 or 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

December 20, 2013

**Date of Report (Date of earliest event reported)**

**INVIVO THERAPEUTICS HOLDINGS CORP.**

**(Exact Name of Registrant as Specified in Charter)**

**NEVADA**  
**(State or Other Jurisdiction of**  
**Incorporation)**

**000-52089**  
**(Commission File Number)**

**36-4528166**  
**(IRS Employer Identification No.)**

**One Kendall Square, Suite B14402**

**Cambridge, Massachusetts 02139**

**(Address of Principal Executive Offices) (Zip Code)**

**(617) 863-5500**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 8-K

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure.**

On December 20, 2013, the Food and Drug Administration informed InVivo Therapeutics Holdings Corp. (the Company ) that the Company should expect the agency s response to the Company s November 22, 2013 protocol amendments during the week of December 23, 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INVIVO THERAPEUTICS HOLDINGS CORP.**

Date: December 20, 2013

By: /s/ Michael J. Astrue  
Michael J. Astrue

Interim Chief Executive Officer